You are here: Industry Insights > I-Mab

News List

I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease prnasia
August 02, 2021
I-Mab announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) submission for Protollin, an investigational drug to treat Alzheimer's disease, enabling a Phase 1 clinical trial to be initiated.
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million prnasia
July 30, 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that its Board of Directors has authorized a new stock repurchase program. With the Board's authorization ...
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China prnasia
July 29, 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa (also known as ...
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange prnasia
July 28, 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that on July 27, 2021, the Board of Directors of the Company approved a preliminary proposal for the ...
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms prnasia
July 12, 2021
I-Mab announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody prnasia
July 12, 2021
ABL Bio, Inc. announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in the Journal for ImmunoTherapy of Cancer(JITC).
I-Mab Expands Next-Gen Novel Oncology Portfolio contractpharma
July 12, 2021
I-Mab, a clinical stage biopharmaceutical company developing novel biologics, signed two new collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company.
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio prnasia
July 02, 2021
I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced multiple advancements in its 4-1BB bispecific antibody portfolio.
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus prnasia
June 28, 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has ...
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board prnasia
June 22, 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced the appointment of Andrew Zhu, MD, PhD, to the Company's Scientific Advisory Board.

Previous page 1 2 3 4 5 6 Next page